Items tagged with Drug-resistant TB
RESIST-TB November 2023 newsletter (post)
RESIST-TB released its November 2023 newsletter with the latest updates and research publications on drug-resistant TB.
South African TB study finds evidence of bedaquiline-resistance transmission (post)
A study of tuberculosis (TB) patients in South Africa found that more than half receiving treatment with a bedaquiline-containing regimen had isolates with bedaquiline resistance, researchers reported in The Lancet Microbe.
Janssen submits Phase 3 study data to the European Medicines Agency and U.S. Food and Drug Administration for SIRTURO® (bedaquiline) (post)
STREAM Stage 2 study data submitted as part of Type II Variation to European Medicines Agency and supplemental New Drug Application to U.S. FDA aim to support the full and traditional approval in the European Union and U.S., respectively.
TB Alliance applauds Macleods’ launch of a key component of WHO-recommended drug-resistant TB treatment regimen (post)
Macleods becomes second pharmaceutical manufacturer to bring pretomanid supply to market and first since the World Health Organization issued updated DR-TB treatment guidelines.
New drug-resistant TB treatments reach patients in Pakistan as Association for Social Development accelerates pilot implementation (post)
ISLAMABAD and PRETORIA (9 November 2023)—The Association for Social Development (ASD) has registered 206 participants with drug-resistant tuberculosis (DR-TB) in Pakistan through a pilot program for treatment with new regimens recently recommended by the World Health Organization (WHO), known as BPaL/M – combinations of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin. ASD reported that out of 113 treatment outcomes declared, so far 105 (95%) have been successful—matching the success rates found elsewhere in the world with these new regimens and a drastic improvement over results with prior drug-resistant TB therapies. As an outcome of these positive results, Pakistan has updated its treatment guidelines for DR-TB to enable the use of these six-month, all-oral regimens.
Mozambique faces alarming multidrug-resistant TB epidemic (post)
With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major problem, with 4,800 new cases of multidrug resistant (MDR)/rifampicin-resistant TB in the country estimated in 2021.
TB-PRACTECAL trial reveals efficacy of new oral regimen (post)
In a recent study published in The Lancet Respiratory Medicine, researchers reported the TB-PRACTECAL clinical trial outcomes, which evaluated the efficacy and safety of oral bedaquiline, linezolid, and pretomanid (BPaL)-based regimens for pulmonary tuberculosis resistant to rifampicin.
RESIST-TB December 2023 newsletter (post)
RESIST-TB released its December 2023 newsletter with the latest updates and research publications on drug-resistant TB.
Drug-resistant TB may be under-diagnosed, says genomic analysis in southern Mozambique (post)
A proportion of patients with drug-resistant tuberculosis (TB) receive ineffective treatment due to misdiagnosis by rapid molecular tests, according to a genomic analysis carried out in southern Mozambique and co-led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by "la Caixa" Foundation, and the Institute of Biomedicine in Valencia (IBV), from the Spanish National Research Council (CSIC). The results indicate that new molecular tests need to be developed to detect a wider range of mutations that confer resistance to first-line TB drugs.
Adverse outcomes in drug-resistant TB with diabetes (post)
Diabetes mellitus may lead to adverse outcomes in multidrug-resistant tuberculosis (MDR-TB) or DR-TB, according to systematic review and meta-analysis findings published in BMC Infectious Diseases.
Page 83 of 117 · Total posts: 0
←First 82 83 84 Last→